Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
By E. Pearson, I. Flechtner, P. Njølstad, M. Małecki, S. Flanagan, Brian Larkin, Frances M. Ashcroft, I. Klimeš, E. Codner, V. Iotova and 9 more. New England Journal of Medicine, 2006
967 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/88627f4a032792590623424ed3567f5436b57f4d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Pathology and Forensic Medicine
In Surgery
Citations in the corpus
- Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention (2014, background): “also therapeutic targets for the extensively used pharmaceuticals of T2DM, for example, KCNJ11 and PPARG2 are targets of sulphonylurea and thiazolidinedione classes of drugs widely used for the treatment of T2DM, respectively [36, 37].”
- A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information (2017, background): “This predicted drug-target interaction may be supported by the known clinical evidence that sulfonylureas are usually effective drugs for treating most diabetes patients associated with the KCNJ11 mutations [45, 3].”
- The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021, background): “Genetic testingAsmonogenic diabetes was less likely to have been considered in the past, molecular genetic testing for neonatal diabetes should be considered for all people with type 1 diabetes, regardless of current age, who were diagnosed under 6 months of age as more than 80% have monogenic neona”